Australia's largest stock trading and investment forum Australia's #1 stock forum

SRX

0.00%

17.5¢ sierra rutile holdings limited

SRX OS vs PFS, page-11

First 11 Last

Share
Profile

Follow
madonion87

482 Posts.

09/06/15

23:03

Post #: 15438658
Share

Originally posted by Legume ↑

"Disagree with you on point 4, I don't see any rationale as to why a prolonged liver PFS would have a negative impact at other sites."

Wild1, that was definitely not my contention... I perhaps wasn't clear. The liver PFS is simply a measure of the time it takes for a liver tumour to reach a progressive state and in itself wouldn't impact PFS measures at other sites.

We know every patient that was enrolled in the SIRFLOX study had a liver tumour, and 40% of that population had at least an additional extra-hepatic tumour. If the treatment group had a significant increase in liver only PFS compared to the control group, ie 20.5 vs 12.6, you then have a problem of explaining why the oPFS, ie 10.7 vs 10.2, were the same?

In the scenario that no new tumours are forming during the study period:
~88% of the treatment group (who had an extra tumour) would have had an oPFS reading below 10.7 (based on presentation slides 17+18)
vs
~72% of the control group (who had an extra tumour) would have had an overall PFS reading below 10.2 (as above)

the obvious conclusion is that, if we exclude new tumour formation, then extra-hepatic tumours are progressing at a much faster rate in the SIRT treatment group compared to the control group. Anyway food for thought... It'd be nice if they didn't cherry pick the data.

Expand

What are you talking about? It just means extrahepatic tumours are progressing just as fast

SRX Price at posting: $29.20 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 28 more messages in this thread...

First 11 Last

Add SRX (ASX) to my watchlist

SRX OS vs PFS, page-11

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News